Skip to content
Study details
Enrolling now

Gemcitabine and Nab-Paclitaxel Infusion Schedule for Metastatic Pancreatic Cancer

Anne Noonan
NCT IDNCT04115163ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

53

Study length

about 5.5 years

Ages

18+

Locations

1 site in OH

About this study

This trial is testing a new way to give gemcitabine and nab-paclitaxel, two chemotherapy drugs, to people with pancreatic cancer that has spread. The goal is to see if this schedule improves how well the treatment works.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Gemcitabine
  • 2.Take Nab-paclitaxel
PhasePhase 2
DrugGemcitabine
Routeinjection
Primary goalOverall response rate (ORR)

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low14%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

gemcitabine, paclitaxel (Taxane chemotherapy; stabilizes microtubules)

Drug routes

injection (Injection), infusion

Endpoints

Primary: Overall response rate (ORR)

Secondary: Disease control rate, Incidence of adverse events (AEs), Overall survival (OS), Progression-free survival (PFS)

Body systems

Oncology